Featured Research

from universities, journals, and other organizations

To advance care for patients with brain metastases: Reject five myths

Date:
June 24, 2014
Source:
NYU Langone Medical Center
Summary:
Researchers warn against five misconceptions in treating brain cancers, and offer new perspectives to dispel these myths and improve patient care.

A blue-ribbon team of national experts on brain cancer says that professional pessimism and out-of-date "myths," rather than current science, are guiding -- and compromising -- the care of patients with cancers that spread to the brain.

In a special article published in the July issue of Neurosurgery, the team, led by an NYU Langone Medical Center neurosurgeon, argues that many past, key clinical trials were designed with out-of-date assumptions and the tendency of some physicians to "lump together" brain metastases of diverse kinds of cancer, often results in less than optimal care for individual patients. Furthermore, payers question the best care when it deviates from these misconceptions, the authors conclude.

"It's time to abandon this unjustifiable nihilism and think carefully about more individualized care," says lead author of the article, Douglas S. Kondziolka, M.D., MSc, FRCSC, Vice Chair of Clinical Research and Director of the Gamma Knife Program in the Department of Neurosurgery at NYU Langone.

The authors -- who also say medical insurers help perpetuate the myths by denying coverage that deviates from them -- identify five leading misconceptions that often lead to poorer care:

1. All tumor cell types act the same way once they spread to the brain. This oversimplification means that doctors assume that histologically diverse cancers respond the same way to chemotherapy and are equally sensitive (or insensitive) to radiation. It also means that patients are all assumed to be at the same risk of subsequent brain cancer relapses, and development of additional metastatic lesions; and that survival rates are similar as well. The authors point out that this type of thinking overlooks important biological differences in brain metastases resulting from different types of cancer, such as those originating in the lung, breast or skin.

2. The number of brain metastases is the best indicator for guiding management of the disease. Such strict adherence to quantity, the authors say, can wrongly limit treatment options. Physicians should look at total tumor burden, including the size and scope of metastases, rather than just how many metastases occur.

3. All cancers detectable in the brain already reflect the presence of micrometastases, or smaller, newly formed tumors too miniscule to detect. Evidence, the authors say, suggests otherwise, and aggressively monitoring for, and treating, individual brain metastases can, in fact, improve tumor control and patient survival.

4. Whole brain radiation (WBR) is generally unjustified because it will cause disabling cognitive dysfunction if a patient lives long enough. Dr. Kondziolka and his co-authors say the risks and benefits of WBR should be evaluated for each patient, and that new studies examining the cognitive impact of WBR on thinking and learning are underway.

5. Most brain metastases cause obvious symptoms, making regular screening for them unnecessary, and unlikely to affect survival. The authors counter that advances in screening allow metastases to be detected earlier, and treated sooner, before symptoms occur.

"We are in an era of personalized medicine," Dr. Kondziolka says, "and we need to begin thinking that way." The authors further write: "It is time for fresh thinking and new critical analyses," urging consideration of updated clinical trial designs that include comparison of matched cohorts and cost effectiveness factors. In addition to research that pays more attention to specific cell types and overall tumor burden, investigators should focus on tools available from advances in molecular biology and genetic subtyping and on efforts to learn "why some patients with a given primary cancer develop brain tumors and others do not."

Ultimately, the authors hope better stratifying patients will improve care for patients with diverse brain metastases.

In addition to Dr. Kondziolka from NYU Langone Medical Center, the co-authors represent other major academic medical centers with national reputations in the field of neurosurgery, radiation oncology and neuro-oncology: Steven Kalkanis, MD (Henry Ford Health System), Minesh Mehta, MD (University of Maryland Medical Center), Manmeet Ahluwalia, MD (Cleveland Clinic) and Jay Loeffler, MD (Harvard Medical School).


Story Source:

The above story is based on materials provided by NYU Langone Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Douglas Kondziolka, Steven N. Kalkanis, Minesh P. Mehta, Manmeet Ahluwalia, Jay S. Loeffler. It Is Time to Reevaluate the Management of Patients With Brain Metastases. Neurosurgery, 2014; 75 (1): 1 DOI: 10.1227/NEU.0000000000000354

Cite This Page:

NYU Langone Medical Center. "To advance care for patients with brain metastases: Reject five myths." ScienceDaily. ScienceDaily, 24 June 2014. <www.sciencedaily.com/releases/2014/06/140624105050.htm>.
NYU Langone Medical Center. (2014, June 24). To advance care for patients with brain metastases: Reject five myths. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2014/06/140624105050.htm
NYU Langone Medical Center. "To advance care for patients with brain metastases: Reject five myths." ScienceDaily. www.sciencedaily.com/releases/2014/06/140624105050.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Nigeria Ups Ebola Stakes on 1st Death

Nigeria Ups Ebola Stakes on 1st Death

Reuters - Business Video Online (July 29, 2014) Nigerian authorities have shut and quarantined a Lagos hospital where a Liberian man died of the Ebola virus, the first recorded case of the highly-infectious disease in Africa's most populous economy. David Pollard reports Video provided by Reuters
Powered by NewsLook.com
Running 5 Minutes A Day Might Add Years To Your Life

Running 5 Minutes A Day Might Add Years To Your Life

Newsy (July 29, 2014) According to a new study, just five minutes of running or jogging a day could add years to your life. Video provided by Newsy
Powered by NewsLook.com
Ebola Outbreak Poses Little Threat To U.S.: CDC

Ebola Outbreak Poses Little Threat To U.S.: CDC

Newsy (July 29, 2014) The Ebola outbreak in West Africa poses little threat to Americans, according to officials with the Centers for Disease Control and Prevention. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins